Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
6.03
-0.06 (-0.99%)
At close: Dec 20, 2024, 4:00 PM
6.06
+0.03 (0.50%)
After-hours: Dec 20, 2024, 7:58 PM EST
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $26.08M in the quarter ending September 30, 2024, with 147.62% growth. This brings the company's revenue in the last twelve months to $65.18M, up 37.64% year-over-year. In the year 2023, Recursion Pharmaceuticals had annual revenue of $44.58M with 11.88% growth.
Revenue (ttm)
$65.18M
Revenue Growth
+37.64%
P/S Ratio
22.72
Revenue / Employee
$130,368
Employees
500
Market Cap
1.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
Dec 31, 2019 | 2.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Astrana Health | 1.72B |
National HealthCare | 1.22B |
GoodRx Holdings | 790.39M |
Galapagos NV | 290.09M |
MannKind | 267.20M |
ImmunityBio | 7.33M |
CG Oncology | 684.00K |
RXRX News
- 1 day ago - Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules - GlobeNewsWire
- 9 days ago - Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform - Seeking Alpha
- 12 days ago - Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability - GlobeNewsWire
- 12 days ago - Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245 - Seeking Alpha
- 4 weeks ago - Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery - GlobeNewsWire
- 5 weeks ago - Recursion and Exscientia Shareholders Approve the Proposed Combination - GlobeNewsWire
- 5 weeks ago - Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden - GlobeNewsWire
- 7 weeks ago - Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th - GlobeNewsWire